Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

BenevolentAI hires new head of Cheminformatics from The Institute of Cancer Research

BenevolentAI announced today it has hired Dr Nathan Brown, as its new Head of Cheminformatics following the promotion of Mark Davies…

Cheminformatics

BenevolentAI announced today it has hired Dr Nathan Brown BSc (Hons) FRSC, as its new Head of Cheminformatics following the promotion of Mark Davies from Head of Cheminformatics to Vice President of Biomedical Informatics earlier in the year.  

Dr Brown joined the Institute of Cancer Research (ICR), London in 2007 where he founded and led the new In Silico Medicinal Chemistry Group which focused on medicinal chemistry research towards novel cancer treatments. Dr Brown holds a degree in computing from Robert Gordon University, Aberdeen and conducted his doctoral research in the field of Cheminformatics at the University of Sheffield.  Following his PhD he was awarded a Marie Curie Fellowship for two years working with Avantium in Amsterdam and subsequently one of the first to be awarded a prestigious Presidential Research Fellowship for three years, by Professor Mark Fishman, Global Head of Research at the Novartis Institutes for BioMedical Research.

With extensive experience as a software designer Dr Brown has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology. Furthermore Dr Brown is a recent recipient of the Corwin Hansch Award for contributions to computational chemistry. 

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

Jackie Hunter, CEO of Benevolent Bío, the bioscience subsidiary of BenevolentAI, commented

“Nathan Brown is a recognised leader in the field of cheminformatics, molecular informatics and computational chemistry.  He has done exceptional work in the development of innovative anti-cancer therapies in an academic setting and his work is respected and well published.  We are delighted to have Nathan on board.”